Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I/II study of Lutetium Lu 177 JH040182 Injection in FAP-positive advanced solid tumors
CTR20262974Phase 2Active
- Sponsor
- Crystal Nucleus
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 JH040182 in Non-hematologic malignancy, sponsored by Crystal Nucleus. Started Aug 2026; status: active.
02
Drugs
lutetium Lu 177 JH040182
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20262974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262974.